Abstract
Although, the next 15-20 years will shift a majority of the population into
the elderly population group, children will continue to remain the bulk of the
dependent population worldwide with 9 in every 10 people falling into a
pediatric age range in the less developed regions of Africa, Asia and Latin
America. Therefore, the treatment of conditions and diseases affecting
pediatrics and the healthy growth of children are vital to providing a solid
foundation for healthy adults in the future.
Addressing the needs of the pediatric population is a challenge of managing
human responses within a changing tapestry of anatomic, physiologic, and
psychosocial variations. With patients ranging in age from 24 weeks gestation
to 18 years and older, optimal health care and patient outcomes can be
achieved only through an awareness of the developmental phenomena affecting
the responses of infants and children to health problems.
Important regulatory factors are also at work in the pediatric pharmaceutical
market. The recognition of the rights of children to have access to safe and
effective drugs and the needs of healthcare providers to have access to
age-appropriate drug information continues to have a major effect on all areas
of pediatric pharmaceuticals including pediatric biomedical research. The
support of the U.S FDA in mandating pediatric labeling has played an important
role in providing the motivation to manufacturers to work with clinicians and
researchers in academic settings to study both new and established drugs in
children. The result has been and will continue to be an increase in both the
quantity and quality of pediatric drugs worldwide.
This completely updated edition of Kalorama's 2003 study on prescription
pediatric drugs focuses on the following treatment segments:
- Allergy and Respiratory Drugs
- Anti-Infectives
- Cancer Therapies
- Cardiovascular Drugs
- Central Nervous System Drugs
- Gastrointestinal Drugs
- Hormone Drugs
- Other Drugs
The 500-page report includes global statistical information for conditions and
diseases affecting pediatric populations, including detailed discussions and
over 180 exhibits. Each segment provides an
- overview,
- descriptions of products on the market,
- market estimates and forecasts (U.S. and non-U.S.), and
- competitive analysis of leading providers including market share
In addition, the report includes extensive tables of products in R&D and
approved prescription drugs for which additional pediatric information may
produce health benefits in the pediatric population. There are also in-depth
discussions of current issues and trends affecting the industry and what
trends may arise in the future.
The research conducted by Kalorama Information included comprehensive research
of secondary sources such as company literature, databases, investment
reports, and medical and business journals. Person-to-person and telephone
interviews were the primary method of gathering information. Interviews with
over 100 key industry officials, consultants, health care providers, and
government personnel were complied to form the primary basis of
information-specifically revenue and market share data-presented in this
report. Specific interviews with pharmaceutical company representatives
included marketing directors, division managers, and product representatives.
All market data pertain to the world market at the manufacturers' level. The
base year for data was 2004. Historical data are provided for 2002 and 2003
with forecast data provided for 2005 through 2009. Compound annual growth
rates (CAGRs) are provided for the 2002-2004, 2004-2009, and 2002-2009 periods
for each industry segment covered.
| 
View Cart
